Compare CALY & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CALY | MESO |
|---|---|---|
| Founded | 1982 | 2004 |
| Country | United States | Australia |
| Employees | 28000 | 81 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | N/A | N/A |
| Metric | CALY | MESO |
|---|---|---|
| Price | $13.98 | $14.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $16.50 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 262.6K |
| Earning Date | 05-07-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.23 | $644.56 |
| Revenue Next Year | N/A | $38.63 |
| P/E Ratio | $64.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.26 | $9.88 |
| 52 Week High | $16.65 | $21.50 |
| Indicator | CALY | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 50.44 | 47.16 |
| Support Level | $13.18 | $14.44 |
| Resistance Level | $13.96 | $16.77 |
| Average True Range (ATR) | 0.48 | 0.59 |
| MACD | 0.08 | 0.07 |
| Stochastic Oscillator | 44.83 | 41.47 |
Callaway Golf Co is a golf equipment, gear and apparel company with a portfolio of world-wide brands, including Callaway Golf, Odyssey, TravisMathew, and OGIO. Callaway designs, manufactures, and sells high-performance golf clubs, golf balls, apparel, bags, and other accessories-setting the standard for performance in the game of golf. The company has two operating and reportable business segments: Golf Equipment and Apparel, Gear and Other. Geographically, the company operates in United States, Europe, Asia, and Rest of World, of which it derives maximum revenue from United States.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.